Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes.

Vuong BT, Delépine CM, Ratter-Rieck JM, Rinaldi E, Julla JB, Cussenot E, Diedisheim M, Raverdy V, Liu E, Fischer JS, Hepprich M, Alzaid F, Blériot C, Becht E, Cornuot C, de Keizer J, Abdelouahab MB, Chiral M, Pfeil R, Lipaeva P, Dörr D, Zaharia OP, Jolivet T, Alberge J, Potier C, Khider K, Oger F, Riveline JP, Vidal-Trecan T, Tubach F, Estellat C, Abecassis J, Silvin A, Hadjadj S, Varoquaux G, Wagner R, Froguel P, Bonnefond A, Saulnier PJ, Pattou F, Ginhoux F, Roden M, Trombetta M, Potier L, Herder C, Gautier JF, Donath MY, Bonadonna RC, Venteclef N.

Open source

DOI
10.1016/j.cmet.2026.07.027
Published
2026-08-25
Container
Cell Metab
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.cmet.2026.07.027,
  title = {Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes.},
  author = {Vuong BT and  Delépine CM and  Ratter-Rieck JM and  Rinaldi E and  Julla JB and  Cussenot E and  Diedisheim M and  Raverdy V and  Liu E and  Fischer JS and  Hepprich M and  Alzaid F and  Blériot C and  Becht E and  Cornuot C and  de Keizer J and  Abdelouahab MB and  Chiral M and  Pfeil R and  Lipaeva P and  Dörr D and  Zaharia OP and  Jolivet T and  Alberge J and  Potier C and  Khider K and  Oger F and  Riveline JP and  Vidal-Trecan T and  Tubach F and  Estellat C and  Abecassis J and  Silvin A and  Hadjadj S and  Varoquaux G and  Wagner R and  Froguel P and  Bonnefond A and  Saulnier PJ and  Pattou F and  Ginhoux F and  Roden M and  Trombetta M and  Potier L and  Herder C and  Gautier JF and  Donath MY and  Bonadonna RC and  Venteclef N.},
  year = {2026},
  journal = {Cell Metab},
  doi = {10.1016/j.cmet.2026.07.027},
  url = {https://doi.org/10.1016/j.cmet.2026.07.027}
}

RIS

TY  - JOUR
TI  - Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes.
AU  - Vuong BT
AU  -  Delépine CM
AU  -  Ratter-Rieck JM
AU  -  Rinaldi E
AU  -  Julla JB
AU  -  Cussenot E
AU  -  Diedisheim M
AU  -  Raverdy V
AU  -  Liu E
AU  -  Fischer JS
AU  -  Hepprich M
AU  -  Alzaid F
AU  -  Blériot C
AU  -  Becht E
AU  -  Cornuot C
AU  -  de Keizer J
AU  -  Abdelouahab MB
AU  -  Chiral M
AU  -  Pfeil R
AU  -  Lipaeva P
AU  -  Dörr D
AU  -  Zaharia OP
AU  -  Jolivet T
AU  -  Alberge J
AU  -  Potier C
AU  -  Khider K
AU  -  Oger F
AU  -  Riveline JP
AU  -  Vidal-Trecan T
AU  -  Tubach F
AU  -  Estellat C
AU  -  Abecassis J
AU  -  Silvin A
AU  -  Hadjadj S
AU  -  Varoquaux G
AU  -  Wagner R
AU  -  Froguel P
AU  -  Bonnefond A
AU  -  Saulnier PJ
AU  -  Pattou F
AU  -  Ginhoux F
AU  -  Roden M
AU  -  Trombetta M
AU  -  Potier L
AU  -  Herder C
AU  -  Gautier JF
AU  -  Donath MY
AU  -  Bonadonna RC
AU  -  Venteclef N.
PY  - 2026
JO  - Cell Metab
DO  - 10.1016/j.cmet.2026.07.027
UR  - https://doi.org/10.1016/j.cmet.2026.07.027
ER  -

APA

BT, V., CM, D., JM, R., E, R., JB, J., E, C., M, D., V, R., E, L., JS, F., M, H., F, A., C, B., E, B., C, C., J, D. K., MB, A., M, C., R, P., P, L., D, D., OP, Z., T, J., J, A., C, P., K, K., F, O., JP, R., T, V., F, T., C, E., J, A., A, S., S, H., G, V., R, W., P, F., A, B., PJ, S., F, P., F, G., M, R., M, T., L, P., C, H., JF, G., MY, D., RC, B., & N., V. (2026). Immunometabolic endotypes define distinct clinical trajectories in type 2 diabetes.. Cell Metab. https://doi.org/10.1016/j.cmet.2026.07.027

Source records